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Received September 3, 1985 Models for predicting the effect of immunological recognition of the bridge group on the doseresponse curves obtained with heterogeneous hapten enzyme immunoassays are presented. Appropriate theoretical treatment shows that the greater affinity of antibodies toward the enzymelabeled species than for the unlabeled hapten analyte results in assays with limited detection capabilities.
This problem is compounded when enzyme conjugates possessing multiple haptens are used. In equilibrium type competitive arrangements. the concentrations of binder and labeled hapten may be optimized to some extent to improve assay performance.
However. the results presented show that only when assays are performed in a sequential binding mode using carefully controlled timing of reagent incubations can the detection capabilities of the assays be fully maximized for analyte measurements.
Unfortunately, it is also shown that such sequential binding approaches render the assays essentially nonselective. The elfect of decreasing the affinity of the binder to the enzyme-labeled hapten relative to the unlabeled analyte by using heterologous conjugates in equilibrium arrangements is shown to improve detection capabilities but also at the expense of reduced selectivity. Suggestions for reagent concentrations and conjugate substitution (degree of conjugation).
which provide optimized dose-response curves at a given EDSo value, are also presented as are proposals for using different binders which do not exhibit bridging group recognition.
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The use of enzymes rather than radioisotopes as labels in competitive binding assays has resulted in the development of a wide range of new enzyme immunoassay (EIA)3 techniques for measurement of important biological molecules (I-3) . While the use of enzymes may overcome some of the costs and hazards associated with conventional radioimmunoassay (RIA) procedures, the detection capabilities of such methods can often be limited. In some cases the detection limits can be drastically affected by antibody recognition of the bridging group which cova- ' lently links the hapten (ligand) to the enzyme label (4) (5) (6) (7) (8) (9) . Since this same link is usually utilized in the preparation of hapten protein immunogens used to elicit antibody formation, the resulting antibodies typically have a much higher affinity toward the enzyme-labeled hapten than for unlabeled analyte. The purpose of this report is to theoretically (based on a mass-action model) predict the behavior of assays in which this dissimilarity in binding affinities exists and to examine how variation in reagent concentrations and actual methodology (equilibrium vs sequential binding) can affect the dose-response
curves. An approach for optimizing reagent concentrations in equilibrium methods is also presented.
Bridging group recognition problems are also often observed in classical RIA procedures, particularly when there is no method BACHAS AND MEYERHOFF for directly radiolabeling the haptenic species (10-12). For example, in RIAs of steroids, hemisuccinate derivatives of the steroids are used to couple these molecules to radioiodinated tyrosine to form the labeled reagent. The same hemisuccinate derivatives are also used to prepare the immunogen needed for antibody production, and in these reports it is clearly shown that the resulting antisera have a higher affinity for the hemisuccinate derivative than for the unmodified steroid. Similar problems can occur in newer fluoroimmunoassay methods where the fluorescent tag must be covalently linked to hapten to form the labeled reagent (7) . However, the problem is magnified considerably in EIAs since the derivatized hapten is typically linked to the enzyme through a lysine residue. Thus, aside from the derivatized arm of the hapten (e.g., hemisuccinate) the bridging group also includes this lysine residue of the protein. Since the original immunogen also possesses the same derivative-lysine link, antibodies are likely to have an even greater affinity for labels containing the exact same sequence of bonds (i.e., enzyme-hapten conjugates). In general. the smaller the hapten species, the greater the chances of significant bridging group recognition problems.
creased. Thus, the statistical association constant between the binder and the labeled species is increased, which further enhances the effect of bridging group recognition on assay performance. Aside from the multiplicity issue, our theoretical analysis is based on plotting dose-response curves as bound vs logarithm of analyte concentration. While this type of plotting of EIA results is very common, there is a lack of theoretical treatment of this case, particularly when associated with the effect of bridging group recognition and multiple substitution of the label on assay performance. Furthermore, in this report there is a theoretical approach to nonequilibrium curves obtained when sequential binding methodologies are employed. Such a theoretical treatment is unique in the case of unequal binding affinities and, in view of the suggested advantages of the sequential binding approach for overcoming bridging group recognition, may aid in optimizing this alternate method.
Although theoretical treatments have already been reported for the case where labeled and unlabeled ligands demonstrate different affinities for the binder in immunoassays ( 13-16), these results apply to techniques which employ monosubstituted labeled species, such as RIA and fluoroimmunoassay. However, it is very common that the enzyme conjugates used in hapten EIAs are multivalent, with more than one ligand attached per enzyme molecule. The number of hapten molecules per molecule of enzyme depends on the conditions of the coupling reaction, as well as on the nature of both the enzyme and the hapten, and may vary from 1: 1 to 30: 1 or more. In this case the effective concentration of the Iabeled ligand (i.e., ligand molecules attached to sites on the enzyme that are stereochemically unrestricted to approach by the binder) is inResearchers have already proposed practical approaches to solve the bridging recognition problem in EIAs (4) (5) (6) 17, 18) . The most logical approach is to reduce the affinity (association) constant between the labeled species and the antibody binder. Typically this is done by using a structurally different bridge for preparing the labeled species than was used in the original immunogen (5.6) . Empirically, it has been shown that this heterologous approach can improve the assay response toward the analyte but often decrease the selectivity of the assay. We now demonstrate that this decrease in selectivity can be predicted based on appropriate theoretical treatment of the relative change in affinity between the antibody and the labeled species, the analyte, and the interferent (e.g., cross-reacting substance). (20) . In this case, the amount of bound enzyme conjugate is also inversely related to the quantity of analyte. The protocols for both of these assays usually involve some type of separation step after an appropriate incubation time (heterogeneous assays). This is accomplished either by immobilizing the antibody to a solid support or by using immobilized second antibody which has high affinity for the hapten-specific antibody (2 1).
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Once the activity of the enzyme is determined in the solid phase, a dose-response curve is plotted from the data obtained with standards, and the concentration of the unknown is inferred from this curve. For the single-incubation enzyme immunoassay technique, labeled and unlabeled haptens are mixed first. followed by addition of the antibody and subsequent incubation of the mixture until equilibrium is achieved. The equilibrium expressions for this approach can be formulated as P+Q = QP, K P* + Q = QP*. K* [II where P is the unlabeled hapten (standard or sample), P* is the enzyme-hapten conjugate, and Q is the antibody. K and K* are the association constants for the two reactions. The initial concentrations of P, P*, and Q will be symbolized by a, a*, and q, respectively. The antibody will be considered immobilized on a solid support such that no dissociation of the antibody from the support can take place. In this way the separation of the bound and free fractions is accomplished in a single step. This assumption will be made throughout our BACHAS AND MEYERHOFF theoretical treatment and will simplify the modeling efforts (do not need to consider second equilibrium binding process (22)).
value is an upper limit for KS,,,. Due to steric hindrance or site-site interactions, k',,, is likely to be much smaller. For the case of single-step assays, dose-response curves were simulated assuming a single-incubation equilibrium system which employs a binder possessing univalent, independent, and equivalent binding sites (described in Appendix I). For EIAs, such assumptions are met if a divalent antibody can simultaneously bind two different enzyme-ligand conjugates. It was also assumed that the enzyme conjugate was purified so that it did not contain any unconjugated hapten, any unconjugated enzyme, or any conjugated inactive enzyme.
Equilibrium mode: Efect of conjugute substitution. To demonstrate the effect of the multivalency of the conjugate in the assay, the following model was used. The conjugate, EP,, was assumed to have an effective conjugation ratio (number of ligand molecules attached per enzyme molecule that can be bound by the binder) of 12. Further, the binder can associate with any of the n ligands that are conjugated to the same enzyme, but once the binder binds one of these ligands the other ligands become stereochemically restricted to such a binding and do not participate in any other equilibria. The last assumption is more likely true only when the binder is immobilized on solid support. Finally, the multivalent conjugate will be considered as having independent ligand molecules, each one having the same microscopic association constant (for definition. see Ref. (23) (24) treated the case where the kinetics of the binding reactions for the labeled and unlabeled ligand are identical. However, this is not normally the case when there is bridging group recognition involved and theoretical treatment of this situation has been mentioned (24) but never fully evaluated.
The sequential binding assay involves a preincubation step of the unlabeled ligand with the binder, P+QLzQP.
K=k,lkm,, followed by a second incubation after the labeled ligand has been added to the reaction mixture. During the second incubation both the equilibrium equations P + Q k: QP, K = k,lkm, k2 P* + Q c> QP*, K* = k2/kp2 hold: the various parameters of this system are as defined before for the equilibrium system. k, and k2 are the association rate constants, and k-, and kp2 are the dissociation rate constants of the two reactions. [II] where Q, P, QP, K, and K* are as defined for
Scheme [I] , and Kstit is the association constant of this multivalent conjugate with the binder. Because the binder may bind to any of the n available ligands on the conjugate, it is statistically n times as probable for the binder to associate with the conjugate, K,,,, = nK*. This
The theoretical simulation of this principle is based on a kinetic model similar to that suggested by Rodbard et al. (24) where the first incubation is long enough to allow equilibrium to be reached, while during the second incubation
The model calculates the parameters [PI, [QP] , and [Q] for the first incubation which serve as initial values for the set of Eqs.
[l] and [2] (see Appendix II). For both assay modes (equilibrium and sequential binding), in order to have a more general treatment, unitless parameters were used for the simulations.
This was accomplished by multiplying the various parameters with the association equilibrium constant, K, of the binder for the unlabeled analyte (e.g., dose-response curves of Kbound vs log Kp were generated instead of bound vs logp curves) or dividing by the amount of labeled ligand, p* (e.g.. dose-response curves of bound/a* vs log Kp were used) as described in the appendixes. These approaches allow a more direct comparison of assay performances under various conditions.
All data were obtained using programs written in Commodore BASIC and run on a Commodore CBM Model 8032 desk top computer.
RESUL.TS AND DISCUSSION
Several parameters have been used to define the "sensitivity" of immunoassay systems and this often results in misunderstandings within the competitive binding assay literature (25) (26) (27) and in different conditions for optimized assays (19) . To avoid such a confusion, the term sensitivity will not be used in the following discussion. Instead, to evaluate and compare the performance of each assay modeled. three different parameters will be used as indicated in Fig. 1: (a) the maximum response, Kbo (i.e.. the response at zero dose normalized with respect to K), (b) the KEDso value (i.e., the effective dose that produces 50% of the maximum response, EDZo, again normalized with respect to K). and (c) the steepness of the dose-response curve. (maximum value of d([QP*]/p*)/d(log Kp)) are also used to evaluate the response characteristics of the assays. The Kbo and KEDSD as well as the steepness and relative steepness are calculated as shown in Appendix III. The ED50 value does not necessarily correspond to the inflection point of the dose-response curve. Nevertheless, it is customary to use ED50 values rather than inflection point values to evaluate dose-response curves.
According to these parameters, a limit on the detectability of the tracer will control the minimum affordable Kb,, value. The KEDSO value along with the steepness of the doseresponse curve will then determine the response properties of the assay. In practice, random errors associated with measurement of low levels of bound enzyme-labeled species, pipetting errors, phase separation errors, etc., will statistically determine the detection capabilities of the assays (9, (27) (28) (29) . Such statistical constraints can be evaluated if the response can be fitted to a four-parameter logistic model as suggested by Dudley ef al. (30) . However, this approach cannot be used to predict the absolute effect of reagent concentrations on the characteristics of the dose-response curves. Halfman and Schneider (28, 29) have suggested optimization methods which include such statistical constraints (based on a mass-action model) but their approach is restricted to the simple case of k'* = k', which is even further simplified by assuming that the binder and the analyte are present in the assay system at concentrations greater than 1 /K and that p* > q. The more general approach of Yanagishita and Rodbard (3 1) is restricted to the case of equal affinity of the labeled and unlabeled ligand toward the binder. Consequently, statistical restrictions are not considered here because for our model there is no simple analytical solution for the variance on the dose-response curve. However, in order to suggest reagent concentrations to be used when bridging group recognition occurs, assumptions regarding the minimum amount bound at zero dose, bo, are required, as is discussed later.
In equilibrium type methods, the difference in the affinity constants of the unlabeled and enzyme-labeled ligand for the binder drastically affects the performance of the assays. This effect is summarized in Fig. 1 for values of binder and label concentrations in the range typically found in immunoassays (i.e., Kq = 50, Kp* = 50). In this case and in all subsequent studies the parameters Kg and Kp* refer to concentrations of the species in the assay tube. The same is true for the parameters Kbo, KEDso. steepness, and relative steepness. Curves generated with K*/K ratios of 10 and 100 correspond to the case of relatively higher affinity constants for the conjugated than for the unlabeled ligand, a situation that is often encountered when there is bridging group recognition.
To better predict the properties of the equilibrium assay system for changes in the concentration of the reagents, parametric studies were undertaken. The effects of varying the ratio p*/q on KEDSO and the steepness of the dose-response curve for given Kg (e.g., Kg = 50) are shown in Figs. 2 and 3 . Figure 2 indicates that for given Kg and Kp* values. the lower the K*/K, the lower the KEDSO value and, potentially, the lower the concentration of unlabeled ligand that can be detected. The actual detection limits, however, will be de- termined by several factors, including the detectability of the enzyme-labeled ligand. As can also be seen in Fig. 2 , a minimum value of KEDSO is always observed at or near p*/q = 1. The increase in KEDso is marked as p*/q increases above this minimum, while the rate of increase is slower as p*/q decreases below the minimum. From Fig. 3 it is evident that there is an optimum relationship between K* and K for maximum relative steepness and for given Kg and Kp* values. Indeed, the relative steepness of the dose-response curve is reduced drastically at very high or very low values of K* relative to K. However, it can also be seen that bridging group recognition has less of an effect on the relative steepness of dose-response curves as the labeled ligand concentration approaches or exceeds the binding site concentration.
The effect of combined changes in reagent concentration (Kg and Kp*) on the theoretical model for K*/K = 10 (bridging group recognition) is illustrated in Fig. 4 . In most instances, the use of a lower concentration of binder and/or enzyme-labeled ligand will decrease the KEDSD value. but at the same time decrease the steepness of the curve. The shape of the KEDso contour, at regions where p* > q and q > p*, is almost perpendicular to the Kp* and Kg axes. respectively. Thus, in order to improve the KEDso values when p* > q, a decrease in &I* is necessary while a change in Kq does little to reduce the KEDso value. Equivalently, when q > a*, a decrease in q, not changes in p*, is desired to improve the KEDso value. From this figure it can also be inferred that increasing the volume of the incubation mixture, which is equivalent to simultaneously decreasing the concentrations of both q and p*. will improve the EDso but at the expense of the steepness of the dose-response curve. The same general conclusions can be drawn for the case where K*/K = 1 (Fig. 5) . However, when there is no bridging An optimized assay protocol should employ an enzyme conjugate concentration, p*, so that its enzymatic activity can be easily monitored within a reasonably short measuring period, 'Therefore, it is critical to employ an enzyme conjugate with high specific enzymatic activity for which sensitive detection techniques are available (i.e.. fluorescence). To demonstrate the utility of Figs. 4 and 5 in optimizing assays, a hypothetical assay to measure an analyte with a desired EDSo value of 2 X 10e9 M is presented (if 100 ~1 of sample is used m a total assay volume of I ml. the corresponding ED50 for the sample will be 2 X IO-" M). This assay assumes an antibody association constant toward the unlabeled ligand of 5 X 10" M-' (log KEDSO = 2) and a K*/K ratio of 10. A further assumption is that the concentration of the enzyme conjugate bound to the immobilized binder is high enough so that a sufficient absorbance signal can be measured in the zero dose tube over a relative short period of time (e.g., 30 min). This b0 value is highly dependent on the molecular weight and the specific activity of the enzyme label. For this example, a value of 2 X 10-l ' M was assumed as a minimum requirement for b0 (KbO = 1). In the case of alkaline phosphatase, a label commonly used in enzyme immunoassays, this b. corresponds to an absorbance signal of 0.666 after 30 min incubation of the enzyme with the substrate (absorbance of sample minus the absorbance of the blank) assuming a molecular weight of 100,000 (32) and a specific activity of 500 units/mg for the enzyme (the product of the enzymatic reaction, p-nitrophenol, has an t405 = 18.5 X lo3 M-' cm-'). Based on these assumptions, to optimize a dose-response curve to attain given ED5~ and required minimum bo values. the reagent p* and q concentrations can be easily found from Fig. 4 as the points on the log KEDSO contour that give values of Kbo 2 1. Since, in general, the desired two contours intersect at two points, two solutions are possible for each specific requirement for EDso and b. values. The intersect that gives p* > q is preferred since this conserves binder and at the same time yields dose-response curves with steepnesses similar to the alternate solution, when the curves are plotted as bound labeled vs log dose. However, if the response curves are examined as bound labeled vs dose (rectangular coordinates), it is evident that the first set of reagent concentrations also results in curves with better initial slopes compared to the solution when p* < q, and therefore, lower concentrations of analyte may be determined.
the enzyme with the substrate(s), and thus, faster assays. For example, the dose-response curve that corresponds to Kq = 2 and Kp* = 10 will have a Kbo value of 1.98. The almost twice as high Kbo value (compared to the one obtained when Kq = 1.01 and Kp* = 10. 4) allows the use of a 15-min, rather than a 30-min, incubation time period to generate the same absorbance signal of 0.666. However, if the b. value is too high, problems may occur because either the incubation time would need to be too short (n-reproducible results may thus be obtained) or the absorbance would be too high to be measured accurately. In comparison, for the same p* and q, if no bridging group recognition were to occur (K*/K = 1 ), a lower ED5o value would be obtained without substantial reduction of b. (see Fig. 5 ).
The effect of the multivalency of the conjugate on the relative steepness and ICEDSO values of dose-response curves is shown in Fig.   6 for initial K*/K ratios of 10, 1, and 0.1. As noted earlier, increasing the number of ligands attached to the enzyme label effectively causes K* to become nK* = KS,,,, where n is the number of ligands attached to sites capable of being bound by the immobilized binder. This model applies when one assumes that once a ligand is bound by the binder, other ligands on the enzyme cannot also bind to the solid From Fig. 4 , the concentrations of the reagents that will yield the desired assay response curve using the minimum amount of binder possible are 2.08 X 10P" M for a* and 2.02 X lo-" M for q. Note that the steepness (absolute) of the curves can be improved by increasingp* and/or q on the given ED50 contour above these two intersection points. Such steepness is associated with higher bo values which may permit a lower incubation time of FIG. 6 . Effect of conjugate substitution on log KEDSo (curves A) and relative steepness (curves B) for three initial K*/K values: K*/K = 10 (-). K*/K = 1 (---). and K*/ K = 0. I (-* -* -). These curves were generated for equilibrium assays and Kq = ii>* = 50.
phase. This assumption may or may not be bination of two or more of the heterology types true, but serves as a conservative model since, is also possible (5) . In all their studies such if multiple ligands attached to the same en-approaches resulted in improved detection zyme could be bound simultaneously this limits of the assays but at the expense of rewould increase K,,,, enormously (up to lo4 duced selectivity. times, Ref. (33)) and make bridging group This technique of lowering the binding afrecognition problems even worse. It is evident finity between the enzyme-labeled species and from Fig, 6 that at least in the case of an en-the binder has been modeled for the case of zyme conjugate that possesses a chemical Kq = Kp* = 50 and for K/K, = 100, where K, bridge recognizable by the binder (K*/K > 1), is the association constant of the binder with the use of a multivalent conjugate will worsen the interferent (Fig. 7) . A heterologous assay the detection capabilities of the assay. This will reduce K* without affecting the K and K,. theoretical finding is in agreement with ex-As shown. a reduction in the K* will improve perimental data ( 11, 34) .
the detection capabilities toward the analyte From the above discussions, whenever K* as reflected by the KEDso values but at the > K, detection capabilities of the immunoassame time, the selectivity (ID,,/ED,,: ID50 says, in particular EIAs, deteriorate. Several equals the effective dose of the interferent that techniques have been used in practice to overproduces 50% of the maximum response) decome this bridging group recognition problem.
teriorates substantially (i.e., increased crossFor example, Van Weemen and Schuurs (4) reactivity). first realized the importance of heterology in A second approach for improving enzymetheir EIA for estrogens. Improved detection linked competitive binding assays has recently limits were obtained when the estrogen derivbeen suggested by this research team (17,18). atives employed for the preparation of the imThis approach involves the use of endogenous munogen and the enzyme conjugate were binding proteins rather than antibodies. These structurally related but different than the anbinding proteins are either specific globular alyte. By employing such a technique, the afprotein molecules with binding sites for a parfinity constant between the antibody and enticular ligand (e.g., serve to transport ligands zyme-labeled hapten is reduced without any within the body) or they may be certain enchange in the affinity between the binder and the unlabeled hapten. Thus, the unlabeled hapten has a better chance to compete with the conjugate for the binding sites of the an- AMP. This approach, however, resulted in re- P 40 duced selectivity over cyclic GMP. zymes which possess allosteric ligand binding sites. Since the binder production need not be elicited by immunological procedures, there should be a naturally similar or higher affinity for the unlabeled than for the enzyme-labeled ligands (i.e., K*/K 5 1). As shown in Figs. 2, and 3 this situation gives rise to improved steepness and lower KEDso values. Such assays involving the use of appropriate binding proteins (immobilized on a solid phase support) in conjunction with a ligand-enzyme conjugate have been developed for the detection of folate, vitamin B,?, and thyroxine (17,18). Naturally, such binding protein systems can be utilized only if they bind the analyte and the enzyme-labeled ligand with the high affinity necessary to detect low levels of analyte. Further, the selectivity obtained with such systems is controlled by the natural affinities of the binding protein toward the analyte and the respective interferents.
A third approach to solve the bridging group recognition problem is to perform assays using a sequential binding technique. Such a technique is dependent on kinetics rather than thermodynamics and is controlled by two sets of association and dissociation rate constants (see above model).
A collection of values of association rate constants (37) for polyclonal antibodies with various radiolabeled haptens indicated relatively small differences. Values fell roughly in the IO-fold range of IO' to IO* M-' SK' (10' M-' so' is the proposed diffusion controlled limit for this rate constant if the electrostatic repulsions between the hapten and the antibody are taken into account (38) ) while the dissociation rate constants varied in a lOOOfold range. Smith and Skubitz (39) observed that the dissociation rate constants corresponding to the kinetics of the hapten with its respective hapten-specific antibody were lower than those corresponding to the same antibody with a hapten similar in structure but different than the one used to induce the antibody production. For example, rabbit digitoxin specific antibody had association rate constants of 1.4
[3H]digitoxin, [3H]digoxin, and ["Hlouabain, respectively. On the other hand, the respective dissociation rate constants were 2.3 X 10m4, 1.2 X 10e3, and 1.4 X lo-' ss'.
Generally, in sequential binding methods the first incubation is carried to equilibrium. Dose-response curves for this case are shown in Fig. 8 where the second incubation time is varied for fixed P/k and k-z/ii-, ratios. This variation is equivalent to variation in k-,1? values. The unitless parameter k-,fz is used so that either differences in the second incubation time or differences in the dissociation rates of the unlabeled species can be assessed. As expected, an increase in the second incubation time will result in dose-response curves that will eventually approach those obtained using an equilibrium type of assay. A value of kPlfZ = 0.1 is long enough for the label to nearly saturate available binding sites, but short enough so that significant reequilibration does not occur. This value will be used to generate all subsequent sequential binding assay data.
The dose-response curves presented in Fig.  9 were simulated using the parameters given in Table 1 . Curves A,, AZ, and A3 were generated using a P/K ratio of 10 and various LZ/kP, values. Similarly, curves B, , B?, curves of a sequential binding assay for K*/K = 10 and given Kq and Kp*. The first incubation time was considered long enough to allow equilibrium while the second one was varied as indicated by the k-,t, parameter. An equilibrium assay curve was X lo', 1.1 X lo', and 1.3 X 10' M-' SC' with generated usmg same parameters Table I (fixed K9 and A$* values at 50 and fixed second incubation time tL so that km,rz = 0.1). Labels A. B. and C refer to decreasing ratios of K*/K ( IO. I. 0.1). Numerals I through 3 represent the ratios X-Jk-, ( IO. I, 0. I, respectively). Cases AE . BE, and Cc. denote the corresponding equilibrium mode assays.
B3 correspond to a K*/K value of 1, and curves C, , Cl, and C3 to a K*/K ratio of 0.1. In all cases it can be seen that the lower the km7/Li ratio, the shallower the curve and the lower the I& value. Further, the same trend is evident when the K*/K ratio is lowered for a given kP2/kPl ratio. In addition, in the case of low K*/K (e.g., equal to 0.1 and k-2/k-, equal to 10) there was almost no advantage to sequential binding mode over the equilibrium mode assays. An obvious disadvantage of this type of assay protocol is that it involves a second incubation period which must be accurately controlled, thus increasing the time and difficulty of the assay. Further, sequential binding type assays suffer a dramatic deterioration in their selectivity characteristics.
For example, ED5" values of dose-response curves for the analyte and the ratio IDSo/EDSo for the interferent are shown in Table 2 along with the parameters used to generate these curves. In Table 2 it is assumed that all differences in the affinity constants come from differences in the dissociation rate constants while the association rate constants remain unaltered. Based on known data (37, 39) this is a reasonable assumption although it may not be valid in every case. The ED50 values for the analyte and the interferent indicate that in all three cases of Table 2 there is very limited selectivity (IDso values very close to the corresponding ED5o values:) of the assays. This theoretical finding has also been observed experimentally and was empirically explained by a "first come, first served" mechanism (40,4 1) . Thus, unless it is desired to measure a whole class of compounds this mode of assay should be avoided.
In summary. several conclusions can be drawn from the models presented here. For hapten EIAs in which the antibody exhibits bridging group recognition toward the enzyme-labeled species, equilibrium type assays using analyte-enzyme conjugates with the same bridge as the immunogen will result in assays with limited detection capabilities, as defined by high EDso values and a lower steepness for the dose-response curves. In such cases, theory predicts that assay performance can be optimized to lower EDso values by varying the concentrations of binder and/or labeled ligand; however, this will reduce the steepness of the dose-response curve and. concomitantly.
the precision of the method. Further. for given p* or q concentrations, steeper dose-response curves with lower ED5,, 2, 4, 5) . In addition, the models presented suggest the use of conjugates with low hapten to enzyme ratio to avoid compounding the bridging group recognition problem. Equilibrium assays utilizing heterologous conjugates (i.e., different bridging group) may improve the performance of assays, but if the degree of heterology is too excessive, assays with highly reduced selectivity will result. Performing sequential binding type assays will, generally, increase the steepness and lower the ED50 value of the dose-response curve but with a concomitant severe loss of assay selectivity. The concept of using endogenous hapten selective binding proteins rather than antibodies appears to offer a promising new approach since bridging group recognition is completely circumvented. However, such an approach is limited to systems for which there exists a suitable binding protein which will have a high enough affinity toward the analyte and enzyme-labeled conjugate so that competitive binding assays with detection capabilities comparable to traditional immunoassays (e.g., RIAs) will result. Finally, while this study was undertaken to help explain and predict observations in hapten EIA systems, the models and data presented here should help workers developing other types of immunoassays (e.g., fluoroimmunoassays and RIAs) to fully optimize the performance of their tests.
APPENDIX I Mass Action Model of Heterogeneous
Enzyme-Linked Assays
To predict the effect of the difference between K and K* on heterogeneous enzymelinked competitive binding assays, dose-response curves were simulated assuming a single-incubation equilibrium system which employs a binder possessing univalent, independent, and equivalent binding sites and a univalent conjugate. These assumptions lead to the mass action model PSQ = QP, K P* + Q = QP*, K* [II where P is the unlabeled ligand, P* is the ligand-enzyme conjugate, and Q is the specific binder. K and K* are the association constants for the two reactions. The initial concentrations of P, P*, and Q are symbolized by p, p*, and q, respectively. For simplification purposes, the incubation time will be considered long enough to reach equilibrium. Then, the following mass action equations can be written: The sequential binding assay involves two incubation steps. First, the unlabeled ligand is incubated with the binder for a period of time which may or may not be enough to allow complete equilibrium:
This preincubation step is described by the following set of equations: Although analytical solutions ofthis system are available for the case where k, = k2 and km, = k-:! (43, 44) , the system gets quite complicated in the genera1 case of k, # k2 and k-, # km2. Therefore, a numerical solution is necessary. Because of its simplicity, the rectangular rule for numerical integration was employed to solve the differential equations of this model (although better but more complex methods do exist, e.g., Runge-Kutta integration). The two differential equations can then be rewritien as The final values of the parameters are estimated from the second incubation employing an iteration step of li-, At, = 1 X lo-' to ensure accuracy (i.e., if a klt2 value of 0.1 is used, a total of I X lo4 iterations will be undertaken) and successive iterations controlled by the equations This numerical integration procedure was verified for the limiting case of li, = k2 and h--, = li-2 by comparison to the integration method described by Rodbard et al. (24) and the analytical solution of DeLean and Rodbard (44 The Kb,, value is calculated from the described models by setting Kp = 0. To evaluate the KEDSO for the equilibrium model, the value of Kbo/2 is calculated first. Then, the KED50 is estimated numerically by the internal halving method as the value of Kp that corresponds to a K[QP*] value of Kbo/2. The KEDSD in the case of sequential binding assays is determined graphically from the corresponding dose-response curves.
The steepness of a dose-response curve is defined as its maximum slope. This is equivalent to the maximum of the derivative: d(KIQP*l) d(log Kp) .
By taking the derivative of Eq. [6] 4K[QP*l) = KK*p* 4Ql where K[Q] is calculated as described in Appendix I. The maximum of this function, i.e., the steepness of the dose-response curve, is calculated numerically by the golden section method (42) .
The relative steepness is defined as the maximum of the derivative:
cl([QP*l/~*) dlog 0) . which can be evaluated by the golden section method as above.
